uch harder. On the LT, our view remains that there are risks to sustainability of the HCV franchise. Separately, the early approval of idelalisib (CLL & iNHL) was a nice positive offset by the boxed warning and REMS. We still see it as a 10-15% mkt share drug with $1 B+ pot. Capital allocation continues